BioLife Solutions
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 21% of the universe, above its 200-day average.
- Signal has read BUY for 2 months.
- Its last 5 Buy calls have actually lost 19% on average three months out - the strategy's edge here has come from the basket, not from this ticker.
- Recent price momentum is +42.5% on average (3-month/1-year).
- Short interest has risen to 8.2% of float.
- Analyst tilt is Hold.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 32.7x | Better than 19% |
| Forward P/E | 145.1x | Better than 2% |
| Price / Sales | 17.7x | Better than 6% |
| P/E vs own 5-yr range | 92nd pctl | Better than 11% |
Growth B+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 8.1% | Better than 59% |
| Net income CAGR (3Y) | 0.0% | Better than 41% |
| Free cash flow CAGR (3Y) | 63.4% | Better than 88% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 64.6% | Better than 79% |
| Operating margin | -17.3% | Better than 13% |
| Net margin | -4.8% | Better than 20% |
| Return on equity | -1.3% | Better than 26% |
| Return on invested capital | -1.2% | Better than 27% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 4.1% | Better than 82% |
| 6-month return | 61.2% | Better than 97% |
| 12-month return (ex latest month) | 45.5% | Better than 81% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.9x | Better than 89% |
| Debt to assets | 4.4% | Better than 81% |
| Interest coverage | -638.6x | Better than 2% |
| Free cash flow / net income | 75.4% | Better than 24% |
Analyst View F
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 0.0% | Better than 0% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 0.00
- Open
- 0.00
- Day range
- 0.00 - 0.00
- Avg price
- 0.00
- Volume
- 0
- Turnover
- 0
- Turnover ratei
- 0.00%
- Volume ratioi
- 0.00
- Amplitudei
- 0.00%
- 52-week rangei
- 0.00 - 0.00
Valuation
- P/Ei
- -386.10
- P/E (TTM)i
- 32.72
- P/Bi
- 4.50
- EPSi
- -0.10
- Book value / shi
- 8.59
- Net profit
- -4.89M
- Net assets
- 420.01M
Share structure
- Market cap
- 1.89B
- Float capi
- 1.55B
- Shares out
- 48.92M
- Float sharesi
- 40.14M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
Trading activity
Net capital flow main funds, last 45 sessions
-21.36M net over the window
Short interest
- Shares short
- 4.00M
- % of floati
- 8.17%
- Days to coveri
- 4.33
- As of
- 2026-09-30
Frequently asked questions
What is the current stock price of BioLife Solutions (BLFS)?
BioLife Solutions last traded at 0.00. This page shows a periodic quote snapshot. Check the displayed quote time.
What is BioLife Solutions's market cap?
About 1.89B.
What is the P/E ratio of BioLife Solutions?
The trailing twelve-month P/E is 32.72. The Valuation tab shows it against the stock's own five-year range.
Does BioLife Solutions pay a dividend?
BioLife Solutions does not currently pay a regular dividend.
Is BioLife Solutions a buy according to analysts?
The consensus of 6 analysts is a Hold rating, with an average 12-month price target of 31.00. This is not investment advice.
What is BioLife Solutions's StockVane Quant Rating?
The StockVane Momentum strategy currently rates BioLife Solutions a B (Buy). Twelve-month momentum in the top 21% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-21 19:54:59 · For reference only, not investment advice and not tailored to your situation.
BioLife Solutions discussion 0 comments